Zydus Cadila gets tentative USFDA nod for Lorcaserin Hydrochloride Tablets to treat obesity

Lorcaserin Hydrochloride Tablets will be manufactured at the group’s formulations manufacturing facility at $132, Zydus Cadila said in a filing.

New Delhi: Drugmaker Zydus Cadila recently announced that the company has received the tentative approval from the USFDA to market Lorcaserin Hydrochloride Tablets (US RLD — Belviq Tablets), 10 mg to treat obesity.

The drug is used together with diet and exercise to treat obesity.

"It will be manufactured at the group’s formulations manufacturing facility at $132," Zydus said in a BSE filing.

Also Read: Zydus Cadila Desonide Cream, Isosorbide Dinitrate tablets get USFDA approval

The group now has 278 approvals and has so far filed over 330 ANDAS since the commencement of the filing process in FY 2003-04.

Zydus Cadila is a global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 25,000 people worldwide. The company aspires to be a research-based pharmaceutical company by 2020.

Also Read: Zydus Cadila gets tentative USFDA nod for arthritis drug Apremilast